UP!
Durata Therapeutics, established in 2009 in Morristown, New Jersey, is a clinical development stage pharmaceutical company which focuses on the treatment of infectious diseases. The company acquired dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer in December 2009. Durata has initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections. In 2012, the company moved its global headquarters from Morristown to Chicago in a deal with $2 million in tax credits. In October 2014 Durata was acquired by Actavis for about $675 million.
| 2014-10-15 | Downgrade | ROTH Capital | Buy to Neutral | $23 |
| 2014-10-15 | Downgrade | Roth Capital | Buy to Neutral | $23.00 |
| 2014-10-14 | Downgrade | Credit Suisse | Outperform to Neutral | $25.00 |
| 2014-10-14 | Downgrade | Credit Suisse Group AG | Outperform to Neutral | $25.00 |
| 2014-10-07 | Downgrade | RBC Capital | Outperform to Sector Perform | |
| 2014-10-07 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | |
| 2014-10-06 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2014-10-06 | Set Price Target | Roth Capital | $26.00 to $23.00 | |
| 2014-08-08 | Lower Price Target | Jefferies Group | $15.00 to $12.00 | |
| 2014-07-01 | Boost Price Target | Roth Capital | $24.00 to $28.00 | |
| 2014-06-20 | Initiated Coverage | Gabelli | Hold | |
| 2014-06-19 | Reiterated Rating | JMP Securities | Outperform | $19.00 to $22.00 |
| 2014-05-27 | Boost Price Target | Roth Capital | Buy | $21.00 to $24.00 |
| 2014-05-27 | Boost Price Target | RBC Capital | Outperform | $19.00 to $23.00 |
| 2014-05-27 | Boost Price Target | Jefferies Group | Hold | $14.00 to $15.00 |
| 2014-05-23 | Initiated | MLV & Co | Buy | $21 |
| 2014-05-23 | Initiated Coverage | MLV & Co. | Buy | $21.00 |
| 2014-05-22 | Initiated Coverage | MLV & Co. | Buy | $21.00 |
| 2014-04-09 | Initiated | Summer Street Research | Buy | $22 |
| 2014-04-09 | Initiated Coverage | Summer Street | Buy | $22.00 |
| 2014-04-01 | Boost Price Target | Roth Capital | $20.00 to $21.00 | |
| 2014-04-01 | Boost Price Target | RBC Capital | Outperform | $17.00 to $19.00 |
| 2014-04-01 | Boost Price Target | Jefferies Group | $12.40 to $14.00 | |
| 2014-03-25 | Boost Price Target | JMP Securities | Outperform | $14.00 to $18.00 |
| 2014-03-17 | Boost Price Target | Jefferies Group | $10.00 to $12.40 | |
| 2014-03-06 | Initiated Coverage | Roth Capital | Buy | $20.00 |
| 2014-03-06 | Initiated Coverage | Craig Hallum | Buy | |
| 2013-12-02 | Downgrade | Wedbush | Outperform to Neutral | $13.00 |
| 2013-11-13 | Initiated Coverage | Janney Montgomery Scott | Buy | $19.00 |
| 2014-10-15 | Downgrade | ROTH Capital | Buy to Neutral | $23 |
| 2014-10-15 | Downgrade | Roth Capital | Buy to Neutral | $23.00 |
| 2014-10-14 | Downgrade | Credit Suisse | Outperform to Neutral | $25.00 |
| 2014-10-14 | Downgrade | Credit Suisse Group AG | Outperform to Neutral | $25.00 |
| 2014-10-07 | Downgrade | RBC Capital | Outperform to Sector Perform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In DRTX 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM